Results 131 to 140 of about 69,036 (281)

Levodopa versus levodopa sparing in early parkinson’s disease: can we meet halfway?

Revista de Investigación Clínica
Monotherapy is the recommended initial treatment for early Parkinson’s disease. The pharmacological options for initial treatment include dopaminergic agonists, monoamine oxidase B inhibitors, and levodopa formulations.
Mayela Rodríguez-Violante, Ana J. Hernández-Medrano, Amin Cervantes-Arriaga, Cesarina Torres-Vásquez, Dioselina Tristán-Samaniego, Carolina Zepeda-Salazar, Victoria Cerino-Palomino, Arturo Abundes-Velasco   +7 more
doaj   +1 more source

Cortical nicotinic receptors in Alzheimer's disease and Parkinson's disease [PDF]

, 1991
Lange, Klaus W., Wells, F. R., Rossor, M. N., Jenner, P., Marsden, C. D.   +4 more
core   +1 more source

Cortico-striatal gamma oscillations are modulated by dopamine D3 receptors in dyskinetic rats

Neural Regeneration Research
Long-term levodopa administration can lead to the development of levodopa-induced dyskinesia. Gamma oscillations are a widely recognized hallmark of abnormal neural electrical activity in levodopa-induced dyskinesia.
Pengfei Wang, Yuewei Bi, Min Li, Jiazhi Chen, Zhuyong Wang, Huantao Wen, Ming Zhou, Minjie Luo, Wangming Zhang   +8 more
doaj   +1 more source

Severity‐Based and Family‐Centered Approaches to Deep Brain Stimulation in GNAO1‐Related Disorders

Movement Disorders Clinical Practice, EarlyView.
Jana Domínguez‐Carral, Juan Darío Ortigoza‐Escobar   +1 more
wiley   +1 more source

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner, Franziska Eberhardt, Manuela Kofler, Andreas Eigentler, Atbin Djamshidian, Florian Krismer, Anton Hittmair, Heinz Zoller, Valentina Ellinger, Beatrice Heim, Klaus Seppi   +10 more
wiley   +1 more source

Impact of a Public Health Policy on Accessibility to Levodopa for People with Parkinson's Disease in Brazil

Movement Disorders Clinical Practice, EarlyView.
Juliana dos Santos Duarte, Laís Resque Russo Pedrosa, Rafael Sidônio Gibson Gomes, Bruno Lopes Santos‐Lobato   +3 more
wiley   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source

To Exercise at High Intensity Heart Rate or Not to Exercise at High Intensity Heart Rate?

Movement Disorders Clinical Practice, EarlyView.
Daniel M. Corcos, Guillaume Lamotte, Nijee S. Luthra, Kathleen E. McKee   +3 more
wiley   +1 more source

Risk‐Benefit Considerations in Deep Brain Stimulation Discontinuation for Late‐Stage Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Management of deep brain stimulation (DBS) in late‐stage Parkinson's disease (LSPD) remains challenging, particularly when deciding whether to continue or discontinue stimulation, and evidence on risk–benefit considerations is limited. Objectives To identify key factors to improve decision‐making in DBS management for LSPD patients.
Pietro Antenucci, Andrea Gozzi, Fabiana Colucci, Federica Pes, Jay Guido Capone, Alba Scerrati, Michele Alessandro Cavallo, Maura Pugliatti, Daniela Gragnaniello, Mariachiara Sensi   +9 more
wiley   +1 more source

Subthalamic Nucleus Deep Brain Stimulation Improves Kinetic Tremor in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Although resting tremor is a characteristic feature of Parkinson's disease (PD), many patients also suffer from action tremor. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is effective in reducing motor symptoms. However, it is unclear to what extent STN‐DBS improves action tremor in PD, particularly kinetic tremor.
Iwan Grooters, Bart E.K.S. Swinnen, Yarit Wiggerts, Maarten Bot, Pepijn van den Munckhof, P. Rick Schuurman, Martijn Beudel, Rob M.A. de Bie, Arthur W.G. Buijink   +8 more
wiley   +1 more source